BioMarin Announces First Person Treated Commercially With ROCTAVIAN For Severe Hemophilia A In Europe
Portfolio Pulse from Happy Mohamed
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has announced that the first person in Europe has been treated commercially with its gene therapy, ROCTAVIAN, for severe hemophilia A. The treatment took place in Germany, with reimbursement discussions ongoing in France and Italy. In the U.S., ROCTAVIAN is now commercially available and hemophilia treatment centers have begun screening eligible individuals.
August 30, 2023 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioMarin's ROCTAVIAN has been used commercially for the first time in Europe and is now available in the U.S. This could potentially increase the company's revenues and market share in the hemophilia treatment market.
The commercial availability of ROCTAVIAN in Europe and the U.S. represents a significant milestone for BioMarin. This could lead to increased revenues as more patients gain access to the therapy. Additionally, the ongoing reimbursement discussions in France and Italy could further expand the market for ROCTAVIAN, positively impacting BioMarin's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100